To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. Chief Executive Officers, VPs of Regulatory Affairs, heads of Vascular Business Units, and commercial directors from makers of medical devices, cardiovascular pharmaceuticals, and interventional devices were examples of supply-side sources. Procurement leads from tertiary care hospitals, academic medical centers, ambulatory surgery centers, specialized vascular clinics, board-certified interventional cardiologists, vascular surgeons, cath lab medical directors, and hospital pharmacy directors were among the demand-side sources. Primary research confirmed product pipeline timelines for next-generation drug-coated balloons, validated market segmentation across device categories (angioplasty balloons, stents, atherectomy systems) and drug classes (antiplatelets, statins, anticoagulants), and collected information on hospital purchasing dynamics, reimbursement frameworks, and clinical adoption patterns for endovascular procedures.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
By Region: North America (33%), Europe (29%), Asia-Pacific (28%), Rest of World (10%)
Revenue mapping and procedure volume analysis tailored to peripheral interventions were used to determine the global market valuation. The following were part of the methodology:
Finding more than 40 major producers and drug developers with expertise in cardiovascular therapies and endovascular devices across North America, Europe, Asia-Pacific, and Latin America
Product mapping across chronic total occlusion (CTO) systems, atherectomy devices, peripheral stents (covered, bare metal, and drug-eluting), angioplasty balloons, and pharmaceutical categories such as glucose-regulating medications, lipid-lowering treatments, and antiplatelet medicines
Peripheral vascular portfolio-specific analysis of reported and estimated yearly revenues, isolating device sales from medication sales
Coverage of producers and researchers who will account for 75–80% of the world market in 2024
Extrapolation utilizing top-down (pharmaceutical sales data and manufacturer revenue validation) and bottom-up (procedure volume × ASP by country for revascularization procedures, adjusted for hospital vs. ASC settings) approaches to determine segment-specific valuations for devices (catheters, plaque modification, hemodynamic flow alteration) and drug classes
